OBJECTIVE: To compare the clinical outcome of children having severe pneumonia, with and without zinc supplementation by a randomized double-blind placebo controlled trial. METHODS: In this study, 128 children (3-60 months old) admitted to the hospital with severe pneumonia were randomly divided into 2 groups (64 in each) that received either zinc sulfate (2 mg/kg/d, maximum 20 mg in 2 divided doses, for 5 days) or a placebo, along with the standard antimicrobial therapy. Primary outcome measurements included the time taken for clinical symptoms of severe pneumonia such as fever and respiratory distress symptoms to resolve, and the secondary outcome included the duration of hospital stay. RESULTS: The time taken for all the symptoms to resolve in the zinc-supplemented group was significantly lesser then that in the placebo group (42.26 [6.66] vs. 47.52 [7.15] h respectively, p < 0.001). The zinc-treated group had a significantly shorter duration of fever (23.29 [6.67] vs. 26.6 [6.26] h, p = 0.024), respiratory distress (32.87 [7.85] vs. 37.37 [4.43] h, p = 0.001), required a shorter hospital stay (126.74 [12.8] vs. 137.74 [11.52] h, p < 0.001) than did the controls. The zinc supplement was well tolerated by the children. CONCLUSIONS: The results suggest that adjuvant treatment with zinc accelerates recovery from severe pneumonia in young children and significantly reduces the duration of hospital stay. Further studies are required to develop appropriate recommendations for the use of zinc in the treatment of severe pneumonia in other populations.
RCT Entities:
OBJECTIVE: To compare the clinical outcome of children having severe pneumonia, with and without zinc supplementation by a randomized double-blind placebo controlled trial. METHODS: In this study, 128 children (3-60 months old) admitted to the hospital with severe pneumonia were randomly divided into 2 groups (64 in each) that received either zinc sulfate (2 mg/kg/d, maximum 20 mg in 2 divided doses, for 5 days) or a placebo, along with the standard antimicrobial therapy. Primary outcome measurements included the time taken for clinical symptoms of severe pneumonia such as fever and respiratory distress symptoms to resolve, and the secondary outcome included the duration of hospital stay. RESULTS: The time taken for all the symptoms to resolve in the zinc-supplemented group was significantly lesser then that in the placebo group (42.26 [6.66] vs. 47.52 [7.15] h respectively, p < 0.001). The zinc-treated group had a significantly shorter duration of fever (23.29 [6.67] vs. 26.6 [6.26] h, p = 0.024), respiratory distress (32.87 [7.85] vs. 37.37 [4.43] h, p = 0.001), required a shorter hospital stay (126.74 [12.8] vs. 137.74 [11.52] h, p < 0.001) than did the controls. The zinc supplement was well tolerated by the children. CONCLUSIONS: The results suggest that adjuvant treatment with zinc accelerates recovery from severe pneumonia in young children and significantly reduces the duration of hospital stay. Further studies are required to develop appropriate recommendations for the use of zinc in the treatment of severe pneumonia in other populations.
Authors: Palle Valentiner-Branth; Prakash S Shrestha; Ram K Chandyo; Maria Mathisen; Sudha Basnet; Nita Bhandari; Ramesh K Adhikari; Halvor Sommerfelt; Tor A Strand Journal: Am J Clin Nutr Date: 2010-04-07 Impact factor: 7.045
Authors: D Labadarios; N P Steyn; E Maunder; U MacIntryre; G Gericke; R Swart; J Huskisson; A Dannhauser; H H Vorster; A E Nesmvuni; J H Nel Journal: Public Health Nutr Date: 2005-08 Impact factor: 4.022
Authors: Ai Q Truong-Tran; Richard E Ruffin; Paul S Foster; Aulikki M Koskinen; Peter Coyle; Jeffrey C Philcox; Allan M Rofe; Peter D Zalewski Journal: Am J Respir Cell Mol Biol Date: 2002-09 Impact factor: 6.914
Authors: Farshad Hasanzadeh Kiabi; Abbas Alipour; Hadi Darvishi-Khezri; Aily Aliasgharian; Amir Emami Zeydi Journal: Indian J Crit Care Med Date: 2017-01
Authors: Duy T Dao; Lorenzo Anez-Bustillos; Bennet S Cho; Zhilling Li; Mark Puder; Kathleen M Gura Journal: Nutrients Date: 2017-10-28 Impact factor: 5.717
Authors: Bart A Eijkelkamp; Jacqueline R Morey; Stephanie L Neville; Aimee Tan; Victoria G Pederick; Nerida Cole; Prashina P Singh; Cheryl-Lynn Y Ong; Raquel Gonzalez de Vega; David Clases; Bliss A Cunningham; Catherine E Hughes; Iain Comerford; Erin B Brazel; Jonathan J Whittall; Charles D Plumptre; Shaun R McColl; James C Paton; Alastair G McEwan; Philip A Doble; Christopher A McDevitt Journal: PLoS Pathog Date: 2019-08-22 Impact factor: 6.823
Authors: Jorge Alberto Acevedo-Murillo; Miguel Leonardo García León; Verónica Firo-Reyes; Jorge Luis Santiago-Cordova; Alejandra Pamela Gonzalez-Rodriguez; Rosa María Wong-Chew Journal: Front Pediatr Date: 2019-11-14 Impact factor: 3.418
Authors: Sian L Stafford; Nilesh J Bokil; Maud E S Achard; Ronan Kapetanovic; Mark A Schembri; Alastair G McEwan; Matthew J Sweet Journal: Biosci Rep Date: 2013-07-16 Impact factor: 3.840
Authors: Stephen Howie; Christian Bottomley; Osaretin Chimah; Readon Ideh; Bernard Ebruke; Uduak Okomo; Charles Onyeama; Simon Donkor; Onike Rodrigues; Mary Tapgun; Marie Janneh; Claire Oluwalana; Bankole Kuti; Godwin Enwere; Pamela Esangbedo; Conor Doherty; Grant Mackenzie; Brian Greenwood; Tumani Corrah; Andrew Prentice; Richard Adegbola; Syed Zaman Journal: J Glob Health Date: 2018-06 Impact factor: 4.413